A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
Gilles A. Salles
Research Funding - Gilead Sciences
Thomas J. Ervin
Research Funding - Gilead Sciences
Robert Dichmann
Research Funding - Gilead Sciences
Rod Ramchandren
Research Funding - Gilead Sciences
Ray D. Page
Research Funding - Gilead Sciences
Ramakrishna Battini
Research Funding - Gilead Sciences
William E. Lawler
Research Funding - Gilead Sciences
Leanne Holes
Employment or Leadership Position - Gilead Sciences
Adeboye H. Adewoye
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Sven De Vos
Research Funding - Gilead Sciences